TABLE 1.
Baseline demographics and clinical presentation of entire cohort by disease severity
| All (n = 90) | Mild/moderate disease (n = 63) | Severe disease (n = 27) | P-value | |
|---|---|---|---|---|
| Age in years, median (IQR) | 57 (46-68) | 54 (39-64) | 67 (56-74) | .001 |
| Age >60 (%) | 43 (48) | 24 (38) | 19 (70) | .005 |
| Male sex (%) | 53 (59) | 37 (59) | 16 (59) | .96 |
| Race (%) | ||||
| White | 57 (63) | 40 (63) | 17 (63) | .59 |
| Black | 20 (22) | 13 (21) | 7 (26) | |
| Asian | 5 (6) | 5 (8) | 0 (0) | |
| Other | 8 (9) | 5 (8) | 3 (11) | |
| Hispanic ethnicity (%) | 37 (42) | 25 (40) | 12 (44) | .72 |
| Organ transplant (%) | ||||
| Kidney | 46 (51) | 34 (54) | 12 (44) | .90 |
| Lung | 17 (19) | 10 (16) | 7 (26) | |
| Liver | 13 (14) | 9 (14) | 4 (15) | |
| Heart | 9 (10) | 6 (10) | 3 (11) | |
| Heart-kidney | 3 (3) | 2 (3) | 1 (4) | |
| Liver-kidney | 1 (1) | 1 (2) | 0 (0) | |
| Kidney-pancreas | 1 (1) | 1 (2) | 0 (0) | |
| Years from transplant to diagnosis, median (IQR) | 6.64 (2.87-10.61) | 6.25 (2.6-10.69) | 6.86 (2.87-10.16) | .92 |
| Within 1 mo (%) | 3 (3) | 2 (7) | 1 (4) | .90 |
| Within 1 y (%) | 13 (14) | 8 (13) | 5 (19) | .47 |
| Comorbidities (%) | ||||
| HTN | 58 (64) | 37 (60) | 19 (78) | .01 |
| DM | 41 (46) | 27 (43) | 14 (52) | .47 |
| CKD | 57 (63) | 38 (60) | 19 (70) | .47 |
| Dialysis | 5 (6) | 4 (6) | 1 (4) | .57 |
| Chronic lung disease | 17 (19) | 11 (17) | 6 (22) | .65 |
| HIV | 1 (1) | 1 (2) | 0 (0) | .51 |
| Active cancer | 3 (3) | 0 (0) | 3 (11) | .01 |
| BMI > 40 kg/m2 | 5 (6) | 3 (5) | 2 (7) | .63 |
| Presenting symptoms (%) | ||||
| Fever | 63 (70) | 50 (79) | 13 (48) | .01 |
| Fatigue | 25 (28) | 20 (32) | 5 (19) | .30 |
| Myalgias | 22 (24) | 18 (29) | 4 (15) | .24 |
| Cough | 53 (59) | 39 (62) | 14 (52) | .70 |
| Dyspnea | 39 (43) | 22 (35) | 17 (63) | .01 |
| Diarrhea | 28 (31) | 21 (33) | 7 (26) | .68 |
| Vomiting | 7 (8) | 5 (8) | 2 (7) | .95 |
| Days from symptom onset to test, median (IQR) | 4 (2-7) | 4 (2-7) | 4 (1.5-7) | .46 |
| Report of known exposure outside hospital (%) | 15 (17) | 12 (19) | 3 (11) | .41 |
| Suspected nosocomial transmission (%) | 3 (3) | 0 (0) | 3 (11) | .01 |
| Initial SARS-CoV-2 test negative and retested positive (%) | 7 (8) | 3 (5) | 4 (15) | .09 |
| Baseline IS (%) | ||||
| CNI | 77 (86) | 53 (84) | 24 (89) | .38 |
| Mycophenolate | 65 (72) | 44 (70) | 21 (78) | .57 |
| Steroids | 53 (59) | 34 (38) | 19 (70) | .18 |
| Azathioprine | 4 (4) | 4 (6) | 0 (0) | .20 |
| Belatacept | 5 (6) | 4 (6) | 1 (4) | .64 |
| IVIG ± Pheresis | 3 (3) | 1 (2) | 2 (7) | .15 |
| mTOR | 6 (7) | 5 (8) | 1 (4) | .24 |
| Hospitalized (%) | 68 (76) | 41 (65) | 27 (100) | <.001 |
| Days from positive SARS-CoV-2 test until death or last follow-up, median (IQR) | 20 (14-24) | 20 (15-26) | 15 (9-23) | .003 |